Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination
Drug resistance is a significant challenge of daily oncology practice. Docetaxel and gossypol both have antitumoral activity in hormone-refractory prostate cancer (HRPC). Our results revealed that docetaxel and gossypol were synergistically cytotoxic and apoptotic in PC-3 cells in a dose- and time-d...
Gespeichert in:
| Veröffentlicht in: | Molecular biology reports 2010-03, Vol.37 (3), p.1269-1277 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1277 |
|---|---|
| container_issue | 3 |
| container_start_page | 1269 |
| container_title | Molecular biology reports |
| container_volume | 37 |
| creator | Cengiz, Ercument Karaca, Burcak Kucukzeybek, Yuksel Gorumlu, Gurbuz Gul, Mustafa K. Erten, Cigdem Atmaca, Harika Uzunoglu, Selim Karabulut, Bulent Sanli, Ulus A. Uslu, Ruchan |
| description | Drug resistance is a significant challenge of daily oncology practice. Docetaxel and gossypol both have antitumoral activity in hormone-refractory prostate cancer (HRPC). Our results revealed that docetaxel and gossypol were synergistically cytotoxic and apoptotic in PC-3 cells in a dose- and time-dependent manner. We further investigated the expression profiles of genes involved in drug resistance and metabolism with a Human Cancer Drug Resistance and Metabolism PCR Array
®
(SuperArray). Six of the 84 genes that are known to regulate drug resistance, metabolism, cell cycle, DNA repair and oncogenesis were downregulated ≥3-fold change by the combination treatment. These results may be important in devising mechanism-based and targeted therapeutic strategies for prostate cancer, especially in devising combination therapy for drug resistant prostate cancers. |
| doi_str_mv | 10.1007/s11033-009-9501-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_198485281</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1953738121</sourcerecordid><originalsourceid>FETCH-LOGICAL-c370t-267573c7e530e6ac77fdaebaf3d650c9a74fff23a507a040c4c302819ff6e5293</originalsourceid><addsrcrecordid>eNp1kEtPwzAQhC0EgvL4AVyQxRnDOk7q-IgqXhISHOBsuc66BKV2sVNEbvx03IcEF06WvN_O7AwhpxwuOYC8SpyDEAxAMVUBZ8MOGfFKClYqWe-SEYj8WdYVPyCHKb0DQMlltU8OuCrquuBqRL6fPjHaMG_9jDZxOaMRU5t64y3S1tO3EOfBI6PGN-s5i-iisX2IA13EkMkeqV3hkVrsOtq1Hi_o84QJOh1oEyz25gu7tcAspDQsQkez4bT1pm-DPyZ7znQJT7bvEXm9vXmZ3LPHp7uHyfUjs0JCz4qxzMGsxEoAjo2V0jUGp8aJZlyBVUaWzrlCmAqkgRJsaQUUNVfOjbEqlDgi5xvdfPXHElOv38My-mypuapzSRnOEN9ANkdLOapexHZu4qA56FXlelO5zpXrVeV6yDtnW-HldI7N78a24wwUGyDlkZ9h_OP8r-oPaJ2OPQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198485281</pqid></control><display><type>article</type><title>Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Cengiz, Ercument ; Karaca, Burcak ; Kucukzeybek, Yuksel ; Gorumlu, Gurbuz ; Gul, Mustafa K. ; Erten, Cigdem ; Atmaca, Harika ; Uzunoglu, Selim ; Karabulut, Bulent ; Sanli, Ulus A. ; Uslu, Ruchan</creator><creatorcontrib>Cengiz, Ercument ; Karaca, Burcak ; Kucukzeybek, Yuksel ; Gorumlu, Gurbuz ; Gul, Mustafa K. ; Erten, Cigdem ; Atmaca, Harika ; Uzunoglu, Selim ; Karabulut, Bulent ; Sanli, Ulus A. ; Uslu, Ruchan</creatorcontrib><description>Drug resistance is a significant challenge of daily oncology practice. Docetaxel and gossypol both have antitumoral activity in hormone-refractory prostate cancer (HRPC). Our results revealed that docetaxel and gossypol were synergistically cytotoxic and apoptotic in PC-3 cells in a dose- and time-dependent manner. We further investigated the expression profiles of genes involved in drug resistance and metabolism with a Human Cancer Drug Resistance and Metabolism PCR Array
®
(SuperArray). Six of the 84 genes that are known to regulate drug resistance, metabolism, cell cycle, DNA repair and oncogenesis were downregulated ≥3-fold change by the combination treatment. These results may be important in devising mechanism-based and targeted therapeutic strategies for prostate cancer, especially in devising combination therapy for drug resistant prostate cancers.</description><identifier>ISSN: 0301-4851</identifier><identifier>EISSN: 1573-4978</identifier><identifier>DOI: 10.1007/s11033-009-9501-y</identifier><identifier>PMID: 19288219</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Animal Anatomy ; Animal Biochemistry ; Apoptosis - drug effects ; Biomedical and Life Sciences ; Cell Line, Tumor ; Chemotherapy ; DNA, Complementary - genetics ; Dose-Response Relationship, Drug ; Drug resistance ; Drug Resistance, Neoplasm - physiology ; Drug Therapy, Combination ; Enzyme-Linked Immunosorbent Assay ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic - drug effects ; Gossypol - pharmacology ; Histology ; Hormones ; Humans ; Life Sciences ; Male ; Morphology ; Oncology ; Pharmacology ; Prostate cancer ; Prostatic Neoplasms - drug therapy ; Taxoids - pharmacology ; Time Factors</subject><ispartof>Molecular biology reports, 2010-03, Vol.37 (3), p.1269-1277</ispartof><rights>Springer Science+Business Media B.V. 2009</rights><rights>Springer Science+Business Media B.V. 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c370t-267573c7e530e6ac77fdaebaf3d650c9a74fff23a507a040c4c302819ff6e5293</citedby><cites>FETCH-LOGICAL-c370t-267573c7e530e6ac77fdaebaf3d650c9a74fff23a507a040c4c302819ff6e5293</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11033-009-9501-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11033-009-9501-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27902,27903,41466,42535,51296</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19288219$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cengiz, Ercument</creatorcontrib><creatorcontrib>Karaca, Burcak</creatorcontrib><creatorcontrib>Kucukzeybek, Yuksel</creatorcontrib><creatorcontrib>Gorumlu, Gurbuz</creatorcontrib><creatorcontrib>Gul, Mustafa K.</creatorcontrib><creatorcontrib>Erten, Cigdem</creatorcontrib><creatorcontrib>Atmaca, Harika</creatorcontrib><creatorcontrib>Uzunoglu, Selim</creatorcontrib><creatorcontrib>Karabulut, Bulent</creatorcontrib><creatorcontrib>Sanli, Ulus A.</creatorcontrib><creatorcontrib>Uslu, Ruchan</creatorcontrib><title>Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination</title><title>Molecular biology reports</title><addtitle>Mol Biol Rep</addtitle><addtitle>Mol Biol Rep</addtitle><description>Drug resistance is a significant challenge of daily oncology practice. Docetaxel and gossypol both have antitumoral activity in hormone-refractory prostate cancer (HRPC). Our results revealed that docetaxel and gossypol were synergistically cytotoxic and apoptotic in PC-3 cells in a dose- and time-dependent manner. We further investigated the expression profiles of genes involved in drug resistance and metabolism with a Human Cancer Drug Resistance and Metabolism PCR Array
®
(SuperArray). Six of the 84 genes that are known to regulate drug resistance, metabolism, cell cycle, DNA repair and oncogenesis were downregulated ≥3-fold change by the combination treatment. These results may be important in devising mechanism-based and targeted therapeutic strategies for prostate cancer, especially in devising combination therapy for drug resistant prostate cancers.</description><subject>Animal Anatomy</subject><subject>Animal Biochemistry</subject><subject>Apoptosis - drug effects</subject><subject>Biomedical and Life Sciences</subject><subject>Cell Line, Tumor</subject><subject>Chemotherapy</subject><subject>DNA, Complementary - genetics</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug resistance</subject><subject>Drug Resistance, Neoplasm - physiology</subject><subject>Drug Therapy, Combination</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Gene Expression Profiling</subject><subject>Gene Expression Regulation, Neoplastic - drug effects</subject><subject>Gossypol - pharmacology</subject><subject>Histology</subject><subject>Hormones</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Morphology</subject><subject>Oncology</subject><subject>Pharmacology</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Taxoids - pharmacology</subject><subject>Time Factors</subject><issn>0301-4851</issn><issn>1573-4978</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kEtPwzAQhC0EgvL4AVyQxRnDOk7q-IgqXhISHOBsuc66BKV2sVNEbvx03IcEF06WvN_O7AwhpxwuOYC8SpyDEAxAMVUBZ8MOGfFKClYqWe-SEYj8WdYVPyCHKb0DQMlltU8OuCrquuBqRL6fPjHaMG_9jDZxOaMRU5t64y3S1tO3EOfBI6PGN-s5i-iisX2IA13EkMkeqV3hkVrsOtq1Hi_o84QJOh1oEyz25gu7tcAspDQsQkez4bT1pm-DPyZ7znQJT7bvEXm9vXmZ3LPHp7uHyfUjs0JCz4qxzMGsxEoAjo2V0jUGp8aJZlyBVUaWzrlCmAqkgRJsaQUUNVfOjbEqlDgi5xvdfPXHElOv38My-mypuapzSRnOEN9ANkdLOapexHZu4qA56FXlelO5zpXrVeV6yDtnW-HldI7N78a24wwUGyDlkZ9h_OP8r-oPaJ2OPQ</recordid><startdate>20100301</startdate><enddate>20100301</enddate><creator>Cengiz, Ercument</creator><creator>Karaca, Burcak</creator><creator>Kucukzeybek, Yuksel</creator><creator>Gorumlu, Gurbuz</creator><creator>Gul, Mustafa K.</creator><creator>Erten, Cigdem</creator><creator>Atmaca, Harika</creator><creator>Uzunoglu, Selim</creator><creator>Karabulut, Bulent</creator><creator>Sanli, Ulus A.</creator><creator>Uslu, Ruchan</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>RC3</scope></search><sort><creationdate>20100301</creationdate><title>Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination</title><author>Cengiz, Ercument ; Karaca, Burcak ; Kucukzeybek, Yuksel ; Gorumlu, Gurbuz ; Gul, Mustafa K. ; Erten, Cigdem ; Atmaca, Harika ; Uzunoglu, Selim ; Karabulut, Bulent ; Sanli, Ulus A. ; Uslu, Ruchan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c370t-267573c7e530e6ac77fdaebaf3d650c9a74fff23a507a040c4c302819ff6e5293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Animal Anatomy</topic><topic>Animal Biochemistry</topic><topic>Apoptosis - drug effects</topic><topic>Biomedical and Life Sciences</topic><topic>Cell Line, Tumor</topic><topic>Chemotherapy</topic><topic>DNA, Complementary - genetics</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug resistance</topic><topic>Drug Resistance, Neoplasm - physiology</topic><topic>Drug Therapy, Combination</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Gene Expression Profiling</topic><topic>Gene Expression Regulation, Neoplastic - drug effects</topic><topic>Gossypol - pharmacology</topic><topic>Histology</topic><topic>Hormones</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Morphology</topic><topic>Oncology</topic><topic>Pharmacology</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Taxoids - pharmacology</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cengiz, Ercument</creatorcontrib><creatorcontrib>Karaca, Burcak</creatorcontrib><creatorcontrib>Kucukzeybek, Yuksel</creatorcontrib><creatorcontrib>Gorumlu, Gurbuz</creatorcontrib><creatorcontrib>Gul, Mustafa K.</creatorcontrib><creatorcontrib>Erten, Cigdem</creatorcontrib><creatorcontrib>Atmaca, Harika</creatorcontrib><creatorcontrib>Uzunoglu, Selim</creatorcontrib><creatorcontrib>Karabulut, Bulent</creatorcontrib><creatorcontrib>Sanli, Ulus A.</creatorcontrib><creatorcontrib>Uslu, Ruchan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><jtitle>Molecular biology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cengiz, Ercument</au><au>Karaca, Burcak</au><au>Kucukzeybek, Yuksel</au><au>Gorumlu, Gurbuz</au><au>Gul, Mustafa K.</au><au>Erten, Cigdem</au><au>Atmaca, Harika</au><au>Uzunoglu, Selim</au><au>Karabulut, Bulent</au><au>Sanli, Ulus A.</au><au>Uslu, Ruchan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination</atitle><jtitle>Molecular biology reports</jtitle><stitle>Mol Biol Rep</stitle><addtitle>Mol Biol Rep</addtitle><date>2010-03-01</date><risdate>2010</risdate><volume>37</volume><issue>3</issue><spage>1269</spage><epage>1277</epage><pages>1269-1277</pages><issn>0301-4851</issn><eissn>1573-4978</eissn><abstract>Drug resistance is a significant challenge of daily oncology practice. Docetaxel and gossypol both have antitumoral activity in hormone-refractory prostate cancer (HRPC). Our results revealed that docetaxel and gossypol were synergistically cytotoxic and apoptotic in PC-3 cells in a dose- and time-dependent manner. We further investigated the expression profiles of genes involved in drug resistance and metabolism with a Human Cancer Drug Resistance and Metabolism PCR Array
®
(SuperArray). Six of the 84 genes that are known to regulate drug resistance, metabolism, cell cycle, DNA repair and oncogenesis were downregulated ≥3-fold change by the combination treatment. These results may be important in devising mechanism-based and targeted therapeutic strategies for prostate cancer, especially in devising combination therapy for drug resistant prostate cancers.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>19288219</pmid><doi>10.1007/s11033-009-9501-y</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-4851 |
| ispartof | Molecular biology reports, 2010-03, Vol.37 (3), p.1269-1277 |
| issn | 0301-4851 1573-4978 |
| language | eng |
| recordid | cdi_proquest_journals_198485281 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Animal Anatomy Animal Biochemistry Apoptosis - drug effects Biomedical and Life Sciences Cell Line, Tumor Chemotherapy DNA, Complementary - genetics Dose-Response Relationship, Drug Drug resistance Drug Resistance, Neoplasm - physiology Drug Therapy, Combination Enzyme-Linked Immunosorbent Assay Gene Expression Profiling Gene Expression Regulation, Neoplastic - drug effects Gossypol - pharmacology Histology Hormones Humans Life Sciences Male Morphology Oncology Pharmacology Prostate cancer Prostatic Neoplasms - drug therapy Taxoids - pharmacology Time Factors |
| title | Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T09%3A55%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overcoming%20drug%20resistance%20in%20hormone-%20and%20drug-refractory%20prostate%20cancer%20cell%20line,%20PC-3%20by%20docetaxel%20and%20gossypol%20combination&rft.jtitle=Molecular%20biology%20reports&rft.au=Cengiz,%20Ercument&rft.date=2010-03-01&rft.volume=37&rft.issue=3&rft.spage=1269&rft.epage=1277&rft.pages=1269-1277&rft.issn=0301-4851&rft.eissn=1573-4978&rft_id=info:doi/10.1007/s11033-009-9501-y&rft_dat=%3Cproquest_cross%3E1953738121%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=198485281&rft_id=info:pmid/19288219&rfr_iscdi=true |